Tags Archive Navigation
icon
-
Media ReleasePositive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
-
Media ReleaseNovartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
-
Media ReleaseNovartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
-
Media ReleaseNovartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
-
Media ReleaseNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
-
Media ReleaseNovartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
-
Media ReleaseNovartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- › Next page